Programmed Death Ligand-1 and Tumor Mutation Burden Testing of Patients With Lung Cancer for Selection of Immune Checkpoint Inhibitor Therapies: Guideline From the College of American Pathologists, Association for Molecular Pathology, International Association for the Study of Lung Cancer, Pulmonary Pathology Society, and LUNGevity Foundation.

Saved in:
Bibliographic Details
Title: Programmed Death Ligand-1 and Tumor Mutation Burden Testing of Patients With Lung Cancer for Selection of Immune Checkpoint Inhibitor Therapies: Guideline From the College of American Pathologists, Association for Molecular Pathology, International Association for the Study of Lung Cancer, Pulmonary Pathology Society, and LUNGevity Foundation.
Authors: Sholl LM; From the Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts (Sholl)., Awad M; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts (Awad)., Basu Roy U; Translational Science Research Program, LUNGevity Foundation, Chicago, Illinois (Basu Roy)., Beasley MB; the Department of Anatomic Pathology and Clinical Pathology, Mt. Sinai Medical Center, New York, New York (Beasley)., Cartun RW; the Department of Anatomic Pathology, Hartford Hospital, Hartford, Connecticut (Cartun)., Hwang DM; the Department of Laboratory Medicine & Pathobiology, Sunnybrook Health Science Centre, Toronto, Ontario, Canada (Hwang)., Kalemkerian G; the Department of Medical Oncology and Internal Medicine, University of Michigan Health, Ann Arbor (Kalemkerian)., Lopez-Rios F; Pathology Department, Hospital Universitario 12 de Octubre, Madrid, Spain (Lopez-Rios)., Mino-Kenudson M; the Department of Pathology, Massachusetts General Hospital, Boston (Mino-Kenudson)., Paintal A; the Department of Pathology, NorthShore University Health System, Evanston, Illinois (Paintal)., Reid K; Governance (Reid) and the Pathology and Laboratory Quality Center for Evidence-based Guidelines, College of American Pathologists, Northfield, Illinois(Ventura)., Ritterhouse L; the Department of Pathology, Foundation Medicine, Cambridge, Massachusetts (Ritterhouse)., Souter LA; Methodology Consultant, Hamilton, Ontario, Canada (Souter)., Swanson PE; the Department of Laboratory Medicine and Pathology, University of Washington Medical Center, Seattle (Swanson)., Ventura CB; Governance (Reid) and the Pathology and Laboratory Quality Center for Evidence-based Guidelines, College of American Pathologists, Northfield, Illinois(Ventura)., Furtado LV; the Department of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee (Furtado).
Source: Archives of pathology & laboratory medicine [Arch Pathol Lab Med] 2024 Jul 01; Vol. 148 (7), pp. 757-774.
Publication Type: Journal Article; Practice Guideline
Journal Info: Publisher: College of American Pathologists Country of Publication: United States NLM ID: 7607091 Publication Model: Print Cited Medium: Internet ISSN: 1543-2165 (Electronic) Linking ISSN: 00039985 NLM ISO Abbreviation: Arch Pathol Lab Med Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1543-2165
DOI:10.5858/arpa.2023-0536-CP